In the Claims:

Please amend claims 1 and 3 as set forth below. Please add claim 36 as set forth below.

1. (Currently amended) A method for producing therapeutic human T regulatory cells (Treg cells) with enhanced suppressor activity, said method comprising:

selecting a sample of human $CD4^+$ T cells;

contacting said sample with an anti-CD25 antibody;

isolating cells that bind to said anti-CD25 antibody from said sample using a double column magnetic antibody cell sorting (MACS) purification procedure, to produce an isolated population of human $CD4^+CD25^+$ Treg cells; and

culture-expanding said population of human $CD4^+CD25^+$ Treg cells ~~by GMP-approved methods, wherein said culture-expanding comprises~~ comprising contacting said isolated population of human $CD4^+CD25^+$ Treg cells with immobilized anti-CD3 antibody and immobilized anti-CD28 antibody at a predetermined ratio, wherein the ratio of the amount of anti-CD3 antibody to anti-CD28 antibody is less than 1, thereby producing therapeutic human Treg cells with enhanced suppressor activity.

2. (Previously presented) The method of claim 30, wherein said isolation step comprises a high level of stringency.

3. (Currently amended) The method of claim 2, wherein said isolation step further comprises substantially enhancing $CD4^+CD25^{bright}$ cells in said isolated population, while substantially depleting $CD25^{dim}$ cells in said isolated population.

4. (Previously presented) The method of claim 3, wherein said isolating step comprises contacting the selected human $CD4^+$ T cells with 2μl of said anti-CD25 magnetic microbeads per 10^7 total cells, and wherein the double column purification procedure comprises purifying by running the bead/cell composition over a magnetic column to separate bead-bound cells, washing, and re-eluting over a second magnetic column, and again washing until <1-2% of nonsuppressor cells remain in the purified isolate.

5. (Previously presented) The method of claim 1, wherein said culture-expanding step produces an effective amount of suppressor cells to achieve therapeutic suppression of an immune or autoimmune response in a human.

6. (Canceled)

7. (Previously presented) The method of claim 1, wherein said culture-expanding step further comprises contacting said isolated population of human $CD4^+CD25^+$ Treg cells with IL-2.

8. (Previously presented) The method of claim 1, wherein said isolated population of human $CD4^+CD25^+$ Treg cells are expanded at least 10-20 fold in 14 days of culture in said culture-expanding step.

9. (Previously presented) The method of claim 8, wherein said isolated population of human $CD4^+CD25^+$ Treg cells are expanded at least 100-fold by culturing for an additional 1-2 weeks.

10. (Previously presented) The method of claim 1, further comprising generating therapeutic human Treg cell lines that retain long term down-regulatory suppressor function.

11. (Previously presented) The method of claim 1, wherein the sample of human $CD4^+$ T cells is selected from the group consisting of whole or partially purified blood or hematopoietic cells, selected from the group consisting of peripheral blood mononuclear cells, peripheral blood lymphocytes, spleen cells, tumor-infiltrating lymphocytes and lymph node cells, and bone marrow and peripheral bone marrow cells.

12-27. (Canceled)

28. (Previously presented) The method of claim 1, wherein the ratio of the amount of anti-CD3 antibody to anti-CD28 antibody is at least 1:5.

29. (Previously presented) The method of claim 10, wherein said therapeutic human Treg cell lines retain long term down-regulatory suppressor function for at least three weeks.

30. (Previously presented) The method of claim 1, wherein said anti-CD25 antibody is directly conjugated to a magnetic microbead.

31. (Previously presented) The method of claim 1, wherein said MACS purification procedure is an indirect method, wherein said isolating step further comprises contacting said sample to magnetic microbeads conjugated to a secondary agent that binds to said anti-CD25 antibody.

32. (Previously presented) The method of claim 31, wherein said isolating step comprises a high level of stringency.

33. (Previously presented) The method of claim 32, wherein said isolating step further comprises substantially enhancing $CD4^+CD25^{bright}$ cells in said isolated population, while substantially depleting $CD25^{dim}$ cells in said isolated population.

34. (Previously presented) The method of claim 33, wherein said isolating step comprises contacting the selected, anti-CD25 antibody-contacted human $CD4^+$ T cells with 2μl of said magnetic microbeads per 10^7 total cells, and wherein the double column purification procedure comprises purifying by running the bead/cell composition over a magnetic column to separate bead-bound cells, washing, and re-eluting over a second magnetic column, and again washing until <1-2% of nonsuppressor cells remain in the purified isolate.

35. (Previously presented) The method of claim 31, wherein said anti-CD25 antibody is conjugated to FITC and said secondary agent is an anti-FITC antibody.

36. (New) The method of claim 1, wherein the isolated population of human $CD4^+CD25^+$ Treg cells are cultured in the presence of a $CD4^+$ feeder layer or $CD4^+$ feeder layer conditioned medium.